AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06674811 — intervention group
Intervention type: OTHER
Intervention: Blood Draw
Description: When patients are having blood drawn as part of their regular care, extra blood may be drawn for this study. Participants may opt out of this. Blood draws will occur preoperatively and at intervals postoperatively for proteomic, metabolomic, and exposomic testing.
Study NCT06674811 — intervention group
Intervention type: OTHER
Intervention: Clinical Data Review
Description: Clinical data will be collected and stored in a database by study staff. This includes patient demographics, diagnosis characteristics including staging and risk group, treatment characteristics, and outcomes including length of stay following surgical intervention, readmissions, surgical complications including surgical site infection, time off therapy/time to resumption of chemotherapy.
Study NCT06607185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4066434.
Description: Administered orally.
Study NCT06607185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered intravenously.
Study NCT06607185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Administered intravenously.
Study NCT06607185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously.
Study NCT06607185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered intravenously.
Study NCT06607185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered intravenously.
Study NCT06607185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administered intravenously.
Study NCT06607185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: Administered intravenously.
Study NCT06607185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously.
Study NCT06607185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously.
Study NCT06607185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered intravenously.
Study NCT06607185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously.
Study NCT05361980 — intervention group
Intervention type: DEVICE
Intervention: Pediatric orthopaedic implant
Description: Patient receives a pediatric orthopaedic implant as a part of standard clinical care.
Study NCT06600581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMM01-STEM
Description: IMM01-STEM is an allogeneic cell-free secretome product derived from partially differentiated human stem cells derived from a pluripotent embryonic stem cell line that was established from a single donor IVF discarded blastocyst. The cells are cultivated in bioreactors and the product of their secretion is collected, purified and concentrated to a standardized formulation. The secretome contains a mixture of molecules related to immunomodulation, growth, and extracellular matrix remodeling. This intervention is given 2mL twice a week.
Study NCT06600581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline. This intervention is given 2mL twice a week.
Study NCT06600581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMM01-STEM alternating with placebo (saline)
Description: This intervention consists of IMM01-STEM given once a week and placebo given one a week. IMM01-STEM is an allogeneic cell-free secretome product derived from partially differentiated human stem cells derived from a pluripotent embryonic stem cell line that was established from a single donor IVF discarded blastocyst. The cells are cultivated in bioreactors and the product of their secretion is collected, purified and concentrated to a standardized formulation. The secretome contains a mixture of molecules related to immunomodulation, growth, and extracellular matrix remodeling.
Study NCT06447519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ca(OH)2 as intracanal medicament
Description: Ca(OH2 will be used as intracanal medicament for the disinfection of the root canal between appointmnents
Study NCT05977751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FemBloc
Description: Treatment for women who desire non-surgical permanent birth control by occlusion of the fallopian tubes.
Study NCT06676267 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Description: The laparoscopic surgery system is applied to gynecology and 5G remote surgical treatment.
Study NCT05003583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speaking after viewing pictures with negative and neutral valence
Description: Speaking Condition 1: 10 age-appropriate pictures from the International Affective Picture System (IAPS; Lang, Bradley \& Cuthbert, 2005) will be shown to participants. These pictures are classified as high arousal, negative valence stimuli. Participants will be asked to repeat a simple phrase between picture presentations.~Speaking Condition 2: A blank screen will be shown to participants in place of pictures. This condition is classified as low arousal, neutral valence. Participants will be asked to repeat a simple phrase between blank screen picture presentations.
Study NCT06676033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epcoritamab
Description: Samples from subjects receiving epcoritamab on another clinical trial GCT3013-03 will be collected.
Study NCT06659952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV-positive heart transplant
Description: Receipt of heart from HIV-positive deceased donor only as part of this study
Study NCT06664151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Trivalent
Description: Inactivated influenza vaccine, 0.5mL single-dose, pre-filled syringe, via intratumoral (into a tumor) injection per protocol.
Study NCT06609148 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: De Simone formulation probiotic
Description: Subjects will be given De Simone formulation probiotic 900 billion CFU, 3 times per day for 21-24 days
Study NCT06609148 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given a placebo for 21-24 days
Study NCT05097885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub Acute Whole Body Vibration Training
Description: Participants will be given a personal vibration plate to take home with them for training which will last for 12 weeks. For the first four weeks, participants will be asked to complete 10 minutes of WBV per day (1 minute on and up to 1 minute of rest), at least 3-4 days per week. At least 24 hours will be recommended in between sessions during weeks 1-4. Beginning at week 5, participants will be asked to increase WBV time to up to 14 minutes and/or reduce the duration of rest. Beginning at week 9, participants will be asked to increase WBV time to up to 20 minutes and/or reduce the duration of rest.
Study NCT05117008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered IV over approximately 30 minutes at the recommended dose of 2.5 mg/kg IV over 30 minutes on day 1 of every eight-week (+/- three days) cycle for a maximum of 12 cycles. Maintenance therapy with belantamab mafodotin will continue until progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or end of study (maximum of 12 cycles), whichever occurs first.
Study NCT05860504 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance imaging
Description: Sub-group of patients with left ventricular systolic dysfunction will be examined with cMRI
Study NCT05860504 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary CT
Description: Sub-group of patients with left ventricular systolic dysfunction will be examined with CCT
Study NCT06351137 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intravenous administration
Description: Analgesia is administered intravenously.
Study NCT06351137 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intranasal administration
Description: Analgesia is administered intranasally using an atomizer.
Study NCT04822350 — intervention group
Intervention type: DRUG
Intervention: Avelumab
Description: As provided in real world practice
Study NCT06616142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [18F]CETO tracer
Description: PET/CT with para-chloro-2-\[18F\]fluoroethyl-etomidate (\[18F\]CETO) has a high specificity for the steroidogenic enzymes CYP11B1 and CYP11B2, present in the adrenal cortex, and has more favourable tracer characteristics compared to \[11C\]metomidate. Results obtained with this novel tracer seem promising, but its potential value in the subtyping of PA needs to be further established.
Study NCT06616142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone oral
Description: Pre-treatment of dexamethasone prior to 18F CETO PET/CT scan
Study NCT05758181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apical Undermining
Description: The skin at the tip of the wound will be freed to reduce tension.
Study NCT06616142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adrenal vein sampling
Description: Adrenl vein sampling
Study NCT06479174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAMPS-TR
Description: Persons with stroke ( n=20) and at least 1 targeted family member (TFM) (n=20) will engage with the CHAMPS-TR protocol which involves 10 virtual intervention sessions (bi-weekly for 5 weeks) with key elements including metacognitive problem-solving training (i.e., goal setting, guided discovery, strategy development) and vascular risk reduction coaching building on existing American Heart Association (AHA) LE8 content. Probands that are eligible for RS-tDCS (n=10) will receive 5x weekly (weeks 2-5) RS-tDCS applied to the left dorsolateral prefrontal cortex (DLPFC).
Study NCT06671002 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: NSAID
Description: Once randomized to this group the surgical team will elect to prescribe 1 of the following treatment options for post-discharge pain:~* Ibuprofen 10 milligrams(mg)/kilogram (kg) (maximum 600mg) by mouth every 6 hours around the clock for 2 days, then as needed for pain thereafter (40 doses)~* Celecoxib 6mg/kg (maximum 400mg) by mouth once then 3 mg/kg (maximum 200mg) every 12 hours around the clock for 2 days, then as needed for pain thereafter (40 doses)
Study NCT06671002 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Opioid
Description: Once randomized to this group the surgical team will elect to prescribe for 1 of the following treatment options to be given post procedure for post-discharge pain:~* Oxycodone 0.1 mg/kg (maximum 5 mg) by mouth every 4 to 6 hours as needed for pain, number 10 doses.~* Hydromorphone 0.04 mg/kg (maximum mg) by mouth 4 to 6 hours as needed, number 10 doses
Study NCT06671002 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen
Description: Participants will receive 15mg/kg up to 1000mg by mouth every 6 hours around the clock for the first 2 days after discharge from surgery then as needed thereafter (40 doses)
Study NCT06671002 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ibuprofen
Description: Ibuprofen 10mg/kg (maximum 600 mg) by mouth every 6 hours around the clock for 2 days after discharge from surgery then as needed thereafter (40 doses)
Study NCT06672510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATC
Description: The ATC System is designed to mechanically remove emboli and restore blood flow through the pulmonary arteries in patients experiencing acute P
Study NCT04804553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Participants will receive apremilast orally.
Study NCT04804553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apremilast
Description: Participants will receive apremilast orally.
Study NCT06582693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refer2Quit
Description: The Refer2Quit intervention consists of automatic connection to the adult participant's choice of any or all of four evidence-based tobacco treatment options (varenicline, NRT, quitline, and/or smokefreeTXT), as well as motivational counseling provided by the study team. Supportive and motivational text messaging is also included in the intervention to connect or reconnect adult participants to treatments as needed. Text messaging and support would also focus on supporting appropriate use of NRT and/or varenicline if indicated.
Study NCT04804553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive the matching placebo orally.
Study NCT06585787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KarXT
Description: Specified dose on specified days
Study NCT06405737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Description: Subject assigned to receive intranasal administration of oxytocin (24 IU).
Study NCT06405737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal placebo
Description: Subjects assigned to receive intranasal administration of placebo (24 IU).
Study NCT05409053 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open reduction
Description: the displaced fractures will be treated with open reduction so as to achieve the near anatomical alignment
Study NCT05409053 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Closed reduction
Description: the non displaced fractures will be treated with closed reduction and percutaneous pinning
Study NCT05409053 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conservative management
Description: the non displaced fractures will be treated with closed reduction and castor slab
Study NCT06314958 — intervention group
Intervention type: OTHER
Intervention: CENSURE
Description: A panel of CpG sites, whose methylation level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor.
Study NCT04482530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fruit paste matrice
Description: Evaluation of the kinetics of the appearance of nutrients and the metabolic response induced by the consumption of fruit pastes (5 different matrices will be tested: 1 Original recipe, 1 maltodextrine recipe, 1 fructose recipe, 1 isomaltulose recipe and 1 mixed recipe comprising fructose and isomaltulose) in elderly healthy volunteers.
Study NCT05289271 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaxelis™
Description: Vaxelis™ 0.5 mL sterile suspension in prefilled syringe for intramuscular administration.
Study NCT05333627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellbeing Course for Students (Fast Track)
Description: The core Fast-Track lesson includes information on managing their cycle of symptoms, motivation, and an overview of strategies that can be used to manage symptoms of depression and anxiety. After the core lesson, clients can access three additional Do-It-Yourself guides that focus on thought challenging, controlled breathing/activity planning, and behavioural activation/relapse prevention. These materials are able to be accessed out of sequence on a schedule that suits their needs. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
Study NCT05333627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellbeing Course for Students (5 weeks)
Description: The 5-week course consists of four lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
Study NCT05333627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellbeing Course (8 weeks)
Description: The 8-week course consists of five lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
Study NCT05712928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance/movement therapy (eMove)
Description: Ten weekly 60-minute individual dance/movement therapy telehealth sessions (eMove) delivered by a board-certified dance/movement therapist. eMove treatment protocol integrates movement techniques, creative embodiment, the non-verbal aspects of self-awareness and interpersonal communication in treatment. eMove sessions focus on helping the participant to increase physical activity level, increasing participants' energy levels and motivation to stay active and better cope with everyday activities, improving overall functioning; reducing severity of negative symptoms of schizophrenia; and providing participants with a sense of connection and social support by connecting with a therapist. In addition, sessions are individualized to the participant's presenting needs.
Study NCT06585787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study NCT06376799 — intervention group
Intervention type: OTHER
Intervention: Self-questionnaire
Description: Provision of a self-questionnaire in digital or paper format for the patient. The patient will be asked to indicate their preferences regarding the primary and secondary objectives of the study.
Study NCT04798001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops
Description: Single intranasal dose on Day 1, by intranasal drops
Study NCT04798001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops
Description: Single intranasal dose on Day 1, by intranasal drops
Study NCT04798001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops
Description: Single intranasal dose on Day 1, by intranasal drops
Study NCT04798001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops
Description: Intranasal dose on Day 1 by intranasal drops. Followed by a second, identical dose on Day 36 by intranasal drops
Study NCT04798001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray
Description: Single intranasal dose on Day 1, by intranasal spray
Study NCT05833347 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Distance between Skin-Hyoid Bone(DSHB)
Description: Hyoid bone-skin distance Other Name: DSHB
Study NCT05833347 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Distance between Skin-Vocal Cord Anterior Commissura(DSAC)
Description: Vocal cord anterior commissura-skin distance Other Name: DSAC
Study NCT05833347 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Distance between Skin-Epiglottic(DSE)
Description: Skin-epiglottic distance Other Name: DSE
Study NCT06046339 — intervention group
Intervention type: OTHER
Intervention: Collection of data from the patient's medical file
Description: Collection of data from the patient's medical file.
Study NCT06503224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.
Description: A single intravenous infusion of anti-BCMA and CD19 CART cells (dose-escalating infusion of 0.5-3 x10\^6 CART cells/kg）.
Study NCT05188950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: depression screening test App
Description: The participants' use of the depression screening test App of 6 modules for 12 weeks, at least once a week, 20 minutes per once.
Study NCT06679153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVN461 Ophthalmic Solution 1.0%
Description: VVN461 Ophthalmic Solution, 1.0%, for up to 28 days
Study NCT06679153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVN461 Ophthalmic Solution 0.5%
Description: VVN461 Ophthalmic Solution, 0.5%, for up to 28 days
Study NCT06679153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone acetate
Description: Prednisolone acetate, 1%, for up to 28 days
Study NCT06678971 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIFA 11+
Description: The FIFA 11+ protocol consists of fifteen exercises organized into three segments, with three levels of difficulty. The first segment includes six running exercises, the second focuses on six exercises to enhance lower body strength, balance, and agility, and the third segment involves three running exercises aimed at activating the cardiovascular system.